SD-101 Plus Pembrolizumab Elicits Responses in Head and Neck Cancer
Cancer Therapy Advisor,
The combination of pembrolizumab and intratumoral SD-101 produced responses in patients with recurrent or metastatic head and…
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II TrialSD-101 with Pembrolizumab in PD-1…
Overview of attention for article published in Clinical Cancer Research, March 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (87th percentile)
-
Good Attention Score compared to outputs of the same age and source (65th percentile)
Readers on
- mendeley
- 39 Mendeley